Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis

Bedaquiline (BDQ, B) is the first-in-class diarylquinoline to be approved for treatment of tuberculosis (TB). Recent guidelines recommend its use in treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB). The newly approved regimen combining BDQ with pretomanid and linezoli...

Descripción completa

Detalles Bibliográficos
Autores principales: Almeida, Deepak, Converse, Paul J., Li, Si-Yang, Upton, Anna M., Fotouhi, Nader, Nuermberger, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597756/
https://www.ncbi.nlm.nih.gov/pubmed/34570644
http://dx.doi.org/10.1128/AAC.01412-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597756/
https://www.ncbi.nlm.nih.gov/pubmed/34570644
http://dx.doi.org/10.1128/AAC.01412-21

Ejemplares similares